

Overview of Colorectal papers

Volume 3 Number 9 September 2004

A ProctoSite's e-publication

www.proctosite.com

June 2004 / August 2004

Colorectal Cancer

Surgical treatment

[Ooi SE, Chen GW, Chou CT.](#) Adequate nourishment through total parenteral nutrition treatment may augment immune function in patients with colon cancer. Arch Med Res. 2004 Jul-Aug;35(4):289-93.

[Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA, Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M, Rat P.](#) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004 Aug 15;22(16):3284-92.

[Kam MH, Seow-Choen F, Peng XH, Eu KW, Tang CL, Heah SM, Ooi BS.](#) Minilaparotomy left iliac fossa skin crease incision vs. midline incision for left-sided colorectal cancer. Tech Coloproctol. 2004 Aug;8(2):85-8.

[Balague C, Targarona EM, Sainz S, Montero O, Bendahat G, Kobus C, Garriga J, Gonzalez D, Pujol J, Trias M.](#) Minimally Invasive Treatment for Obstructive Tumors of the Left Colon: Endoluminal Self-Expanding Metal Stent and Laparoscopic Colectomy. Preliminary Results. Dig Surg. 2004 Aug 11

[Martling A, Singnomklao T, Holm T, Rutqvist LE, Cedermark B.](#) Prognostic significance of both surgical and pathological assessment of curative resection for rectal cancer. Br J Surg. 2004 Aug;91(8):1040-5.

[Law WL, Chu KW.](#) Anterior resection for rectal cancer with mesorectal excision: a prospective evaluation of 622 patients. Ann Surg. 2004 Aug;240(2):260-8.

[Walker KG, Bell SW, Rickard MJ, Mehanna D, Dent OF, Chapuis PH, Bokey EL.](#) Anastomotic leakage is predictive of diminished survival after potentially curative resection for colorectal cancer. Ann Surg. 2004 Aug;240(2):255-9.

[Lin JJ, Ye F, Song ZF.](#) Minilaparotomy approach for curative resection of colorectal cancer Zhejiang Da Xue Xue Bao Yi Xue Ban. 2004 Jul;33(4):357-60. Chinese

[Iizuka I, Koda K, Seike K, Shimizu K, Takami Y, Fukuda H, Tsuchida D, Oda K, Takiguchi N, Miyazaki M.](#) Defecatory malfunction caused by motility disorder of the neorectum after anterior resection for rectal cancer. Am J Surg. 2004 Aug;188(2):176-80

[Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR.](#) Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. *Cancer*. 2004 Jul 15;101(2):281-8.

[Laso CA, Gonzalez JJ, Fresno F, Azcano E, Sanz L, Navarrete E.](#) Prognostic value of micrometastases in esophageal and colorectal carcinoma (a clinical experience). *Hepatogastroenterology*. 2004 Jul-Aug;51(58):964-7.

[Lei WZ, Zhao GP, Cheng Z, Li K, Zhou ZG.](#) Gastrointestinal decompression after excision and anastomosis of lower digestive tract. *World J Gastroenterol*. 2004 Jul 1;10(13):1998-2001

[Alexander D, Chatla C, Funkhouser E, Meleth S, Grizzle WE, Manne U.](#) Postsurgical disparity in survival between African Americans and Caucasians with colonic adenocarcinoma. *Cancer*. 2004 Jul 1;101(1):66-76

[Tekkis PP, Kinsman R, Thompson MR, Stamatakis JD.](#) [Association of Coloproctology of Great Britain, Ireland.](#) The Association of Coloproctology of Great Britain and Ireland study of large bowel obstruction caused by colorectal cancer. *Ann Surg*. 2004 Jul;240(1):76-81

[Gerard JP, Chapet O, Nemoz C, Hartweg J, Romestaing P, Coquard R, Barbet N, Maingon P, Mahe M, Baulieux J, Partensky C, Papillon M, Glehen O, Crozet B, Grandjean JP, Adeleine P.](#) Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the Lyon R96-02 randomized trial. *J Clin Oncol*. 2004 Jun 15;22(12):2404-9.

[Munro AJ, Bentley AH.](#) Deprivation, comorbidity and survival in a cohort of patients with colorectal cancer. *Eur J Cancer Care (Engl)*. 2004 Jul;13(3):254-62.

[Laurent C, Sa Cunha A, Rullier E, Smith D, Rullier A, Saric J.](#) Impact of microscopic hepatic lymph node involvement on survival after resection of colorectal liver metastasis. *J Am Coll Surg*. 2004 Jun;198(6):884-91.

[Poletto AH, Lopes A, Carvalho AL, Ribeiro EA, Vieira RA, Rossi BM, Aguiar S Jr, Guimaraes GC, Ferreira Fde O, Nakagawa WT.](#) Pelvic exenteration and sphincter preservation: an analysis of 96 cases. *J Surg Oncol*. 2004 Jun 1;86(3):122-7.

[Piso P, Dahlke MH, Mirena P, Schmidt U, Aselmann H, Schlitt HJ, Raab R, Klempnauer J.](#) Total mesorectal excision for middle and lower rectal cancer: a single institution experience with 337 consecutive patients. *J Surg Oncol*. 2004 Jun 1;86(3):115-21. Review.

[Glehen O, Cotte E, Schreiber V, Sayag-Beaujard AC, Vignal J, Gilly FN.](#) Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. *Br J Surg*. 2004 Jun;91(6):747-54.

[Verwaal VJ, van Tinteren H, van Ruth S, Zoetmulder FA.](#) Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. *Br J Surg*. 2004 Jun;91(6):739-46.

[Kronberg U, Lopez-Kostner F, Soto G, Zuniga A, Wistuba I, Miranda V, Pinto E, Viviani P, Marshall G.](#) Detection of lymphatic micrometastases in patients with stages I and II colorectal cancer: impact on five-year survival. *Dis Colon Rectum*. 2004 Jul;47(7):1151-7.

[Vironen JH, Sainio P, Husa AI, Kellokumpu IH.](#) Complications and survival after surgery for rectal cancer in patients younger than and aged 75 years or older. *Dis Colon Rectum*. 2004 Jul;47(7):1225-31.

[Akbari RP, Paty PB, Guillem JG, Weiser MR, Temple LK, Minsky BD, Saltz L, Wong WD.](#) Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy. *Dis Colon Rectum*. 2004 Jul;47(7):1136-44.

[Cecil TD, Sexton R, Moran BJ, Heald RJ.](#) Total mesorectal excision results in low local recurrence rates in lymph node-positive rectal cancer. *Dis Colon Rectum*. 2004 Jul;47(7):1145-9;

[Capussotti L, Massucco P, Muratore A, Amisano M, Bima C, Zorzi D.](#) Laparoscopy as a prognostic factor in curative resection for node positive colorectal cancer: results for a single-institution nonrandomized prospective trial. *Surg Endosc*. 2004 Jul;18(7):1130-5.

[Bretagnol F, Rullier E, Laurent C, Zerbib F, Gontier R, Saric J.](#) Comparison of functional results and quality of life between intersphincteric resection and conventional coloanal anastomosis for low rectal cancer. *Dis Colon Rectum*. 2004 Jun;47(6):832-8.

[Read TE, Andujar JE, Caushaj PF, Johnston DR, Dietz DW, Myerson RJ, Fleshman JW, Birnbaum EH, Mutch MG, Kodner IJ.](#) Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status. *Dis Colon Rectum*. 2004 Jun;47(6):825-31.

[Nguyen WD, Mitchell KM, Beck DE.](#) Risk factors associated with requiring a stoma for the management of anal cancer. *Dis Colon Rectum*. 2004 Jun;47(6):843-6.

Adjuvant therapy

[Onate-Ocana LF, Montesdeoca R, Lopez-Graniel CM, Aiello-Crocifoglio V, Mondragon-Sanchez R, Cortina-Borja M, Herrera-Goepfert R, Oros-Ovalle C, Gallardo-Rincon D.](#) Identification of Patients with High-risk Lymph Node-negative Colorectal Cancer and Potential Benefit from Adjuvant Chemotherapy. *Jpn J Clin Oncol*. 2004 Jun;34(6):323-8.

[Minsky BD.](#) Combined modality therapy of resectable rectal cancer: current approaches. *Tech Coloproctol*. 2004 Aug;8(2):67-76.

[Smith RE, Colangelo L, Wieand HS, Begovic M, Wolmark N.](#) Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. *J Natl Cancer Inst*. 2004 Aug 4;96(15):1128-32.

[Negri F, Musolino A, Cunningham D, Pastorino U, Ladas G, Norman AR.](#) Retrospective study of resection of pulmonary metastases in patients with

advanced colorectal cancer: the development of a preoperative chemotherapy strategy. *Clin Colorectal Cancer*. 2004 Jul;4(2):101-6.

[Martenson JA Jr, Willett CG, Sargent DJ, Mailliard JA, Donohue JH, Gunderson LL, Thomas CR Jr, Fisher B, Benson AB 3rd, Myerson R, Goldberg RM.](#) Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. *J Clin Oncol*. 2004 Aug 15;22(16):3277-83.

[Guillem JG, Moore HG, Akhurst T, Klimstra DS, Ruo L, Mazumdar M, Minsky BD, Saltz L, Wong WD, Larson S.](#) Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. *J Am Coll Surg*. 2004 Jul;199(1):1-7.

[Mityr E, Douillard JY, Van Cutsem E, Cunningham D, Magherini E, Mery-Mignard D, Awad L, Rougier P.](#) Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. *Ann Oncol*. 2004 Jul;15(7):1013-7.

[Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L.](#) Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. *J Clin Oncol*. 2004 Aug 15;22(16):3395-407. Epub 2004 Jun 15.

[Zondor SD, Medina PJ.](#) Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. *Ann Pharmacother*. 2004 Jul-Aug;38(7-8):1258-64.

[Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer \(MOSAIC\) Investigators.](#) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *N Engl J Med*. 2004 Jun 3;350(23):2343-51.

[Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F.](#) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med*. 2004 Jun 3;350(23):2335-42.

[Tang R, Wang JY, Fan CW, Tsao KC, Chen HH, Wu CM, Chen JS, Changchien CR, Hsieh LL.](#) p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy. *Cancer Lett*. 2004 Jul 8;210(1):101-9.

[Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schoffski P, Sobrero A, Van Cutsem E, Diaz-Rubio E.](#) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. *J Clin Oncol*. 2004 Jun 1;22(11):2084-91.

[Gal R, Sadikov E, Sulkes J, Klein B, Koren R.](#) Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients. *Dis Colon Rectum*. 2004 Jul;47(7):1216-24

Risk factors, staging, follow-up and screening

[Kopp I, Bauhofer A, Koller M.](#) Understanding quality of life in patients with colorectal cancer: comparison of data from a randomised controlled trial, a population based cohort study and the norm reference population. *Inflamm Res*. 2004 Aug;53 Suppl 2:S130-5. Epub 2004 Aug 10.

[Teague BD, Morrison CP, Court FG, Chin VT, Costello SP, Kirkwood ID, Maddern GJ.](#) Role of FDG-PET in surgical management of patients with colorectal liver metastases. *ANZ J Surg*. 2004 Aug;74(8):646-52.

[Mysliwiec PA, Brown ML, Klabunde CN, Ransohoff DF.](#) Are physicians doing too much colonoscopy? A national survey of colorectal surveillance after polypectomy. *Ann Intern Med*. 2004 Aug 17;141(4):264-71

[Fietkau R, Zettl H, Klocking S, Kundt G.](#) Incidence, Therapy and Prognosis of Colorectal Cancer in Different Age Groups A Population-Based Cohort Study of the Rostock Cancer Registry. *Strahlenther Onkol*. 2004 Aug;180(8):478-87.

[Lin J, Zhang SM, Cook NR, Rexrode KM, Lee IM, Buring JE.](#) Body mass index and risk of colorectal cancer in women (United States). *Cancer Causes Control*. 2004 Aug;15(6):581-9.

[Vogt C, Cohnen M, Beck A, vom Dahl S, Aurich V, Modder U, Haussinger D.](#) Detection of colorectal polyps by multislice CT colonography with ultra-low-dose technique: comparison with high-resolution videocolonoscopy. *Gastrointest Endosc*. 2004 Aug;60(2):201-9.

[Van Breda SG, Van Agen E, Engels LG, Moonen EJ, Kleinjans JC, Van Delft JH.](#) Altered vegetable intake affects pivotal carcinogenesis pathways in colon mucosa from adenoma patients and controls. *Carcinogenesis*. 2004 Jul 22

[Gupta D, Lammersfeld CA, Vashi PG, Burrows J, Lis CG, Grutsch JF.](#) Prognostic significance of Subjective Global Assessment (SGA) in advanced colorectal cancer. *Eur J Clin Nutr*. 2004 Jul 14

[UK Colorectal Cancer Screening Pilot Group.](#) Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. *BMJ*. 2004 Jul 17;329(7458):133

[Davies RJ, Collins CD, Vickery CJ, Eyre-Brook I, Welbourn R.](#) Reduction in the proportion of patients with colorectal cancer presenting as an emergency following the introduction of fast-track flexible sigmoidoscopy: a three-year prospective observational study. *Colorectal Dis*. 2004 Jul;6(4):265-7.

[Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, Gerard D, Dassonville F, Bonithon-Kopp C.](#) Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. *Gastroenterology*. 2004 Jun;126(7):1674-80.

[Brown G, Davies S, Williams GT, Bourne MW, Newcombe RG, Radcliffe AG, Blethyn J, Dallimore NS, Rees BI, Phillips CJ, Maughan TS.](#) Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging? *Br J Cancer*. 2004 Jul 5;91(1):23-9.

[Loeve F, van Ballegooijen M, Boer R, Kuipers EJ, Habbema JD.](#) Colorectal cancer risk in adenoma patients: a nation-wide study. *Int J Cancer*. 2004 Aug 10;111(1):147-51

[Rabeneck L, Paszat LF.](#) A population-based estimate of the extent of colorectal cancer screening in Ontario. *Am J Gastroenterol*. 2004 Jun;99(6):1141-4.

[Bandipalliam P, Balmana J, Syngal S.](#) Comprehensive genetic and endoscopic evaluation may be necessary to distinguish sporadic versus familial adenomatous polyposis-associated abdominal desmoid tumors. *Surgery*. 2004 Jun;135(6):683-9.

Metastatic disease

[Rosa F, Meimarakis G, Stahl A, Bumm R, Hahn K, Tatsch K, Dresel S.](#) Colorectal cancer patients before resection of hepatic metastases. Impact of (18)F-FDG PET on detecting extrahepatic disease. *Nuklearmedizin*. 2004 Aug;43(4):135-40.

[Teague BD, Morrison CP, Court FG, Chin VT, Costello SP, Kirkwood ID, Maddern GJ.](#) Role of FDG-PET in surgical management of patients with colorectal liver metastases. *ANZ J Surg*. 2004 Aug;74(8):646-52.

[Vogelsang H, Haas S, Hierholzer C, Berger U, Siewert JR, Prauer H.](#) Factors influencing survival after resection of pulmonary metastases from colorectal cancer. *Br J Surg*. 2004 Aug;91(8):1066-71.

[Negri F, Musolino A, Cunningham D, Pastorino U, Ladas G, Norman AR.](#) Retrospective study of resection of pulmonary metastases in patients with advanced colorectal cancer: the development of a preoperative chemotherapy strategy. *Clin Colorectal Cancer*. 2004 Jul;4(2):101-6.

Molecular biology

[Chin KF, Greenman J, Reusch P, Gardiner E, Marme D, Monson J.](#) Changes in serum soluble VEGFR-1 and Tie-2 receptors in colorectal cancer patients following surgical resections. *Anticancer Res*. 2004 Jul-Aug;24(4):2353-7.

[Church RD, Yu J, Fleshman JW, Shannon WD, Govindan R, McLeod HL.](#) RNA profiling of cyclooxygenases 1 and 2 in colorectal cancer. *Br J Cancer*. 2004 Aug 24

[Takeuchi T, Hisanaga M, Nagao M, Ikeda N, Fujii H, Koyama F, Mukogawa T, Matsumoto H, Kondo S, Takahashi C, Noda M, Nakajima Y.](#) The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination

with MMP-9 serves as an informative prognostic indicator for colorectal cancer. *Clin Cancer Res*. 2004 Aug 15;10(16):5572-9.

[Broll R, Busch P, Duchrow M, Oevermann E, Schwandner O, Farke S, Bruch HP, Windhovel U.](#) Influence of thymidylate synthase and p53 protein expression on clinical outcome in patients with colorectal cancer. *Int J Colorectal Dis*. 2004 Aug 10

[Kanaoka S, Yoshida K, Miura N, Sugimura H, Kajimura M.](#) Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. *Gastroenterology*. 2004 Aug;127(2):422-7.

[Banerjee A, Ahmed S, Hands RE, Huang F, Han X, Shaw PM, Feakins R, Bustin SA, Dorudi S.](#) Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity. *Mol Cancer*. 2004 Aug 06;3(1):21.

[Wu AW, Gu J, Li ZF, Ji JF, Xu GW.](#) COX-2 expression and tumor angiogenesis in colorectal cancer. *World J Gastroenterol*. 2004 Aug 15;10(16):2323-6.

[Zhou ZW, Wan DS, Wang GQ, Pan ZZ, Lu HP, Gao JH, Ding PR.](#) Expression of estrogen receptor and progesterone receptor in colorectal cancer: a quantitative study *Ai Zheng*. 2004 Jul;23(7):851-4. Chinese.

[Deenadayalu VP, Rex DK.](#) Fecal-based DNA assays: a new, noninvasive approach to colorectal cancer screening. *Cleve Clin J Med*. 2004 Jun;71(6):497-503.

[Brand RE, Ross ME, Shuber AP.](#) Reproducibility of a multitarget stool-based DNA assay for colorectal cancer detection. *Am J Gastroenterol*. 2004 Jul;99(7):1338-41

[Shields CJ, Winter DC, Wang JH, Andrews E, Laug WE, Redmond HP.](#) Hypertonic saline impedes tumor cell-endothelial cell interaction by reducing adhesion molecule and laminin expression. *Surgery*. 2004 Jul;136(1):76-83.

[Mak T, Laloo F, Evans DG, Hill J.](#) Molecular stool screening for colorectal cancer. *Br J Surg*. 2004 Jul;91(7):790-800. Review.

[Lage PA, Albuquerque C, Sousa RG, Cravo ML, Salazar M, Francisco I, Maia L, Claro I, Suspiro A, Rodrigues P, Raposo H, Fidalgo PA, Nobre-Leitao C.](#) Association of colonic and endometrial carcinomas in Portuguese families with hereditary nonpolyposis colorectal carcinoma significantly increases the probability of detecting a pathogenic mutation in mismatch repair genes, primarily the MSH2 gene. *Cancer*. 2004 Jul 1;101(1):172-7

[Kunstmann E, Vieland J, Brasch FE, Hahn SA, Epplen JT, Schulmann K, Schmiegel W.](#) HNPCC: six new pathogenic mutations. *BMC Med Genet*. 2004 Jun 24;5(1):16.

[Kim H, Nam SW, Rhee H, Shan Li L, Ju Kang H, Hye Koh K, Kyu Kim N, Song J, Tak-Bun Liu E, Kim H.](#) Different gene expression profiles between microsatellite instability-high and microsatellite stable colorectal carcinomas. *Oncogene*. 2004 Aug 19;23(37):6218-25.

[Croner RS, Guenther K, Foertsch T, Siebenhaar R, Brueckl WM, Stremmel C, Hlubek F, Hohenberger W, Reingruber B.](#) Tissue preparation for gene expression profiling of colorectal carcinoma: three alternatives to laser microdissection with preamplification. *Lab Clin Med.* 2004 Jun;143(6):344-51.

[Tagore KS, Levin TR, Lawson MJ.](#) The evolution to stool DNA testing for colorectal cancer. *Aliment Pharmacol Ther.* 2004 Jun 15;19(12):1225-33.

[Wang JY, Hsieh JS, Chang MY, Huang TJ, Chen FM, Cheng TL, Alexandersen K, Huang YS, Tzou WS, Lin SR.](#) Molecular Detection of APC, K- ras, and p53 Mutations in the Serum of Colorectal Cancer Patients as Circulating Biomarkers. *World J Surg.* 2004 Jun 8

[Lim SB, Jeong SY, Lee MR, Ku JL, Shin YK, Kim WH, Park JG.](#) Prognostic significance of microsatellite instability in sporadic colorectal cancer. *Int J Colorectal Dis.* 2004 Jun 2